Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06571825
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-20
Brief Title:
RIC Allo-HSCT vs Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Comparison to Consolidation Therapy Based Venetoclax for Elderly Patients With Acute Myeloid Leukemia After First CR
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Elderly patients with acute myeloid leukemia AML often face unfavorable prognostic factors such as multiple comorbidities adverse cytogenetic profiles and pre-existing hematological disorders The long-term survival rate remains very low with a 5-year survival rate of only 5 to 10 The introduction of the BCL-2 inhibitor venetoclax Ven has improved the induction remission rates in elderly patients However the question of whether to use chemotherapy maintenance or proceed with allogeneic hematopoietic stem cell transplantation allo-HSCT for post-remission consolidation therapy remains unclear due to the lack of prospective controlled studies Therefore our center plans to conduct a prospective open-label two-arm non-randomized single-center study to further explore the optimal consolidation treatment strategy for elderly AML patients at intermediate and high risk following induction complete remission CR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None